REQUEST A DEMO
Total
USD $0.00
Search more companies

Novavax Cz A.S. (Czech Republic)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Novavax Cz A.S. Profile Updated: May 02, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2022 Available in: English Download a sample report

Novavax Cz A.S. is an enterprise based in Czech Republic. Its main office is in Prague. The enterprise operates in the Pharmaceutical and Medicine Manufacturing industry. Novavax Cz A.S. was incorporated on April 07, 2017. There are currently 250 - 499 (2023) people employed by Novavax Cz A.S.. From the latest financial highlights, Novavax Cz A.S. reported a net sales revenue increase of 113.38% in 2022. Its total assets decreased by 5.99% over the same period. The net profit margin of Novavax Cz A.S. increased by 1.73% in 2022.

Headquarters
Libalova 2348/1
Prague; The City of Prague; Postal Code: 14900

Contact Details: Purchase the Novavax Cz A.S. report to view the information.

Basic Information
Total Employees:
Purchase the Novavax Cz A.S. report to view the information.
Outstanding Shares:
Purchase the Novavax Cz A.S. report to view the information.
Registered Capital:
Purchase the Novavax Cz A.S. report to view the information.
Incorporation Date:
April 07, 2017
Key Executives
Purchase this report to view the information.
Proxy
Purchase this report to view the information.
Proxy
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Novavax Cz A.S. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CZK. Absolute financial data is included in the purchased report.
Net sales revenue
113.38%
Total operating revenue
112.77%
Operating profit (EBIT)
46.02%
EBITDA
57.28%
Net Profit (Loss) for the Period
162.66%
Total assets
-5.99%
Total equity
14.29%
Operating Profit Margin (ROS)
-9.03%
Net Profit Margin
1.73%
Return on Equity (ROE)
7.06%
Quick Ratio
0.29%
Cash Ratio
-0.03%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?